Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors

Oncotarget

Volumn 6, Issue 36, 2015, Pages 38777-38788

  Hoekstra, Attje S ^a   de Graaff, Marieke A ^a   Briaire de Bruijn, Inge H ^a   Ras, Cor ^b   Seifar, Reza Maleki ^b   van Minderhout, Ivonne ^a   Cornelisse, Cees J ^a   Hogendoorn, Pancras C W ^a   Breuning, Martijn H ^a   Suijker, Johnny ^a   Korpershoek, Esther ^c   Kunst, Henricus P M ^d   Frizzell, Norma ^e   Devilee, Peter ^a   Bayley, Jean Pierre ^a   Bovée, Judith V M G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Fumarate hydratase; Hereditary leiomyomatosis and renal cell carcinoma; Methylation; Paraganglioma; Succinate dehydrogenase

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; CARRIER PROTEINS AND BINDING PROTEINS; FUMARATE HYDRATASE; HISTONE; HISTONE H3K27ME3; HISTONE H3K4ME3; HISTONE H3K9ME3; SUCCINATE DEHYDROGENASE; TEN ELEVEN TRANSLOCATION 1; UNCLASSIFIED DRUG; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE; HISTONE LYSINE METHYLTRANSFERASE; MIXED FUNCTION OXIDASE; ONCOPROTEIN; TET1 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; CUTANEOUS LEIOMYOMA; DNA METHYLATION; EPIGENETICS; FH GENE; GENE INACTIVATION; GENE SILENCING; GENOMICS; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEIOMYOMA; LEIOMYOSARCOMA; LOSS OF FUNCTION MUTATION; MUSCLE TUMOR; MUTANT; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROTEIN EXPRESSION; SDH GENE; SKIN TUMOR; STOMACH CHIEF CELL; TISSUE MICROARRAY; TUMOR CELL; UTERUS MYOMA; WILD TYPE; ADRENAL TUMOR; ANALOGS AND DERIVATIVES; CELL NUCLEUS; DEFICIENCY; ENZYMOLOGY; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY;

ADRENAL GLAND NEOPLASMS; CELL NUCLEUS; CYTOSINE; FUMARATE HYDRATASE; GENE SILENCING; HEK293 CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; MIXED FUNCTION OXYGENASES; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROTO-ONCOGENE PROTEINS; SMOOTH MUSCLE TUMOR; SUCCINATE DEHYDROGENASE;

EID: 84948845908     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6091     Document Type: Article

References (44)

1. Burnichon N, Briere JJ, Libe R, Vescovo L, Riviere J, Tissier F, Jouanno E, Jeunemaitre X, Benit P, Tzagoloff A, Rustin P, Bertherat J, Favier J, and Gimenez-Roqueplo AP. SDHA is a tumor suppressor gene causing paraganglioma. Hum.Mol.Genet. 1-8-2010; 1915:3011-3020.
2. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C, and Maher ER. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am.J.Hum.Genet. 2001; 691:49-54.
3. Niemann S and Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nature Genetics. 2000; 263:268-270.
4. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der MA, Taschner PE, Rubinstein WS, Myers EN, Richard CW, III, Cornelisse CJ, Devilee P, and Devlin B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 4-2-2000; 2875454:848-851.
5. Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, Devilee P, Cremers CW, Schiffman JD, Bentz BG, Gygi SP, Winge DR, Kremer H, and Rutter J. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science. 28-8-2009; 3255944:1139-1142.
6. van Schothorst EM, Beekman M, Torremans P, Kuipers-Dijkshoorn NJ, Wessels HW, Bardoel AF, Van Der Mey AG, van der Vijver MJ, van Ommen GJ, Devilee P, and Cornelisse CJ. Paragangliomas of the head and neck region show complete loss of heterozygosity at 11q22-q23 in chief cells and the flow-sorted DNA aneuploid fraction. Hum.Pathol. 1998; 2910:1045-1049.
7. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomaki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, and Aaltonen LA. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat.Genet. 2002; 304:406-410.
8. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, Sistonen P, Herva R, and Aaltonen LA. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc.Natl.Acad.Sci.U.S.A. 13-3-2001; 986:3387-3392.
9. Castro-Vega LJ, Buffet A, De Cubas AA, Cascon A, Menara M, Khalifa E, Amar L, Azriel S, Bourdeau I, Chabre O, Curras-Freixes M, Franco-Vidal V, Guillaud-Bataille M, Simian C, Morin A, Leton R, Gomez-Grana A, Pollard PJ, Rustin P, Robledo M, Favier J, and Gimenez-Roqueplo AP. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum.Mol.Genet. 1-5-2014; 239:2440-2446.
10. Clark GR, Sciacovelli M, Gaude E, Walsh DM, Kirby G, Simpson MA, Trembath RC, Berg JN, Woodward ER, Kinning E, Morrison PJ, Frezza C, and Maher ER. Germline FH mutations presenting with pheochromocytoma. J.Clin.Endocrinol.Metab. 2014; 9910:E2046-E2050.
11. Letouze E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C, Janin M, Menara M, Nguyen AT, Benit P, Buffet A, Marcaillou C, Bertherat J, Amar L, Rustin P, De RA, Gimenez-Roqueplo AP, and Favier J. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell. 10-6-2013; 236:739-752.
12. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, and Tomlinson IP. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum.Mol.Genet. 1-8-2005; 1415:2231-2239.
13. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, and Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005; 71:77-85.
14. Cervera AM, Bayley JP, Devilee P, and McCreath KJ. Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. Mol.Cancer. 2009; 8:89.
15. Smith EH, Janknecht R, and Maher LJ, III. Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum.Mol.Genet. 15-12-2007; 1624:3136-3148.
16. Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, Liu L, Liu Y, Yang C, Xu Y, Zhao S, Ye D, Xiong Y, and Guan KL. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 15-6-2012; 2612:1326-1338.
17. Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, and Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 16-2-2006; 4397078:811-816.
18. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, and Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 15-5-2009; 3245929:930-935.
19. Gu TP, Guo F, Yang H, Wu HP, Xu GF, Liu W, Xie ZG, Shi L, He X, Jin SG, Iqbal K, Shi YG, Deng Z, Szabo PE, Pfeifer GP, Li J, and Xu GL. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature (London). 29-9-2011; 4777366:606-610.
20. Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M, Quezado M, Smith WI, Jr., Jahromi MS, Xekouki P, Szarek E, Walker RL, Lasota J, Raffeld M, Klotzle B, Wang Z, Jones L, Zhu Y, Wang Y, Waterfall JJ, O'Sullivan MJ, Bibikova M, Pacak K, Stratakis C, Janeway KA, Schiffman JD, Fan JB, Helman L, and Meltzer PS. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013; 36:648-657.
21. Pansuriya TC, van ER, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, Cleton-Jansen AM, van Oosterwijk JG, Verbeke SL, Meijer D, van WT, Nord KH, Sangiorgi L, Toker B, Liegl-Atzwanger B, San-Julian M, Sciot R, Limaye N, Kindblom LG, Daugaard S, Godfraind C, Boon LM, Vikkula M, Kurek KC, Szuhai K, French PJ, and Bovee JV. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat.Genet. 2011; 4312:1256-1261.
22. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, and Xiong Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 18-1-2011; 191:17-30.
23. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, and Thompson CB. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (London). 22-3-2012; 4837390:474-478.
24. Bardella C, El-Bahrawy M, Frizzell N, Adam J, Ternette N, Hatipoglu E, Howarth K, O'Flaherty L, Roberts I, Turner G, Taylor J, Giaslakiotis K, Macaulay VM, Harris AL, Chandra A, Lehtonen HJ, Launonen V, Aaltonen LA, Pugh CW, Mihai R, Trudgian D, Kessler B, Baynes JW, Ratcliffe PJ, Tomlinson IP, and Pollard PJ. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J.Pathol. 2011; 2251:4-11.
25. Chen YB, Brannon AR, Toubaji A, Dudas ME, Won HH, Al-Ahmadie HA, Fine SW, Gopalan A, Frizzell N, Voss MH, Russo P, Berger MF, Tickoo SK, and Reuter VE. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am.J.Surg.Pathol. 2014; 385:627-637.
26. Ternette N, Yang M, Laroyia M, Kitagawa M, O'Flaherty L, Wolhulter K, Igarashi K, Saito K, Kato K, Fischer R, Berquand A, Kessler BM, Lappin T, Frizzell N, Soga T, Adam J, and Pollard PJ. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep. 28-3-2013; 33:689-700.
27. Globisch D, Munzel M, Muller M, Michalakis S, Wagner M, Koch S, Bruckl T, Biel M, and Carell T. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS.One. 2010; 512:e15367-
28. Muller T, Gessi M, Waha A, Isselstein LJ, Luxen D, Freihoff D, Freihoff J, Becker A, Simon M, Hammes J, Denkhaus D, zur MA, Pietsch T, and Waha A. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am.J.Pathol. 2012; 1812:675-683.
29. van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, Sleddens HF, Derkx P, Riviere J, Dannenberg H, Petri BJ, Komminoth P, Pacak K, Hop WC, Pollard PJ, Mannelli M, Bayley JP, Perren A, Niemann S, Verhofstad AA, de Bruine AP, Maher ER, Tissier F, Meatchi T, Badoual C, Bertherat J, Amar L, Alataki D, Van ME, Ferrau F, Francois J, de Herder WW, Peeters MP, van LA, Lenders JW, Gimenez-Roqueplo AP, de Krijger RR, and Dinjens WN. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009; 108:764-771.
30. Lendvai N, Pawlosky R, Bullova P, Eisenhofer G, Patocs A, Veech RL, and Pacak K. Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings. Endocrinology. 2014; 1551:27-32.
31. Kiuru M, Lehtonen R, Arola J, Salovaara R, Jarvinen H, Aittomaki K, Sjoberg J, Visakorpi T, Knuutila S, Isola J, Delahunt B, Herva R, Launonen V, Karhu A, and Aaltonen LA. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res. 15-8-2002; 6216:4554-4557.
32. Barker KT, Bevan S, Wang R, Lu YJ, Flanagan AM, Bridge JA, Fisher C, Finlayson CJ, Shipley J, and Houlston RS. Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas. Br.J.Cancer. 12-8-2002; 874:446-448.
33. Lee HY, Choi K, Oh H, Park YK, and Park H. HIF-1-dependent induction of Jumonji domain-containing protein (JMJD) 3 under hypoxic conditions. Mol.Cells. 2014; 371:43-50.
34. Douwes Dekker PB, Corver WE, Hogendoorn PC, Van Der Mey AG, and Cornelisse CJ. Multiparameter DNA flow-sorting demonstrates diploidy and SDHD wild-type gene retention in the sustentacular cell compartment of head and neck paragangliomas: chief cells are the only neoplastic component. J.Pathol. 2004; 2024:456-462.
35. Hensen EF, Goeman JJ, Oosting J, Van Der Mey AG, Hogendoorn PC, Cremers CW, Devilee P, and Cornelisse CJ. Similar gene expression profiles of sporadic, PGL2-, and SDHD-linked paragangliomas suggest a common pathway to tumorigenesis. BMC.Med.Genomics. 2009; 2:25-
36. Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, Chan TA, and Riggins GJ. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 2013; 410:1737-1747.
37. Lehtonen HJ, Makinen MJ, Kiuru M, Laiho P, Herva R, van M, I, Hogendoorn PC, Cornelisse C, Devilee P, Launonen V, and Aaltonen LA. Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability. Int.J.Cancer. 15-9-2007; 1216:1386-1389.
38. de Graaff MA, Cleton-Jansen AM, Szuhai K, and Bovee JV. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity. Hum.Pathol. 2013; 448:1597-1604.
39. Smit DL, Mensenkamp AR, Badeloe S, Breuning MH, Simon ME, van Spaendonck KY, Aalfs CM, Post JG, Shanley S, Krapels IP, Hoefsloot LH, van Moorselaar RJ, Starink TM, Bayley JP, Frank J, van Steensel MA, and Menko FH. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. Clin.Genet. 2011; 791:49-59.
40. Bovee JV, Cleton-Jansen AM, Kuipers-Dijkshoorn NJ, van den Broek LJ, Taminiau AH, Cornelisse CJ, and Hogendoorn PC. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosomes.Cancer. 1999; 263:237-246.
41. Carlotti F, Bazuine M, Kekarainen T, Seppen J, Pognonec P, Maassen JA, and Hoeben RC. Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 adipocytes. Mol.Ther. 2004; 92:209-217.
42. Lorenz MA, Burant CF, and Kennedy RT. Reducing time and increasing sensitivity in sample preparation for adherent mammalian cell metabolomics. Anal.Chem. 1-5-2011; 839:3406-3414.
43. Canelas AB, ten PA, Ras C, Seifar RM, van Dam JC, van Gulik WM, and Heijnen JJ. Quantitative evaluation of intracellular metabolite extraction techniques for yeast metabolomics. Anal.Chem. 1-9-2009; 8117:7379-7389.
44. van Dam JC, Eman MR, Frank J, Lange HC, van Dedem GWK, and Heijnen SJ. Analysis of glycolytic intermediates in Saccharomyces cerevisiae using anion exchange chromatography. Ana.Chim.Acta. 2002; 460:209-218.